Can fibrinogen be elevated in disseminated intravascular coagulation (DIC)?

Can Fibrinogen Be Elevated in DIC?

Yes, fibrinogen can be elevated or normal in disseminated intravascular coagulation (DIC), particularly in early-phase disease, because fibrinogen is an acute-phase reactant that increases during stress and inflammation—only in advanced or fulminant DIC does fibrinogen typically become depleted. 1

Understanding Fibrinogen Dynamics in DIC

The Acute-Phase Response Overrides Consumption

• Fibrinogen is manufactured at a high rate by the liver in response to stress, inflammation, and underlying disease processes, which often keeps levels normal or elevated despite ongoing consumption in DIC. 2
• In early-phase or compensated DIC, fibrinogen levels may remain normal or even elevated as an acute-phase reactant, masking the underlying consumptive coagulopathy. 1
• Only in advanced cases does fibrinogen become depleted when consumption finally exceeds the liver's synthetic capacity. 1

Clinical Evidence Supporting Elevated Fibrinogen in DIC

• In a study of 560 DIC patients, 47% had fibrinogen levels >200 mg/dL, demonstrating that low fibrinogen is not a sensitive marker for DIC diagnosis. 3
• Only 24% of DIC patients had fibrinogen <100 mg/dL, confirming that most patients maintain adequate or elevated levels. 3
• Afibrinogenemia is rare in DIC; fibrinogen is usually high because of the liver's compensatory response to stress. 2

Prognostic Implications of High Fibrinogen

• High fibrinogen levels in DIC patients, particularly those with leukemia/lymphoma, are associated with poor clinical outcomes and increased mortality. 3
• Patients with elevated fibrinogen show less activation of secondary fibrinolysis (lower plasmin-plasmin inhibitor complex and tissue plasminogen activator levels), which impairs clot breakdown. 3
• This inadequate fibrinolytic response leads to persistent microvascular thrombosis, increased organ failure, and worse outcomes. 3
• Among leukemia/lymphoma patients with DIC, the frequency of organ failure was markedly high in those with elevated fibrinogen levels. 3

Diagnostic Approach: Don't Rely on Fibrinogen Alone

Key Laboratory Patterns

• Thrombocytopenia from platelet consumption is the most consistent finding in DIC. 1
• Prolonged prothrombin time reflecting consumption of coagulation factors is characteristic. 1
• Elevated fibrin-related markers (D-dimer, fibrin degradation products) are the most sensitive indicators of ongoing fibrin formation and breakdown. 1
• Fibrinogen levels are unreliable for diagnosis because they can be low, normal, or high depending on disease phase and the balance between consumption and synthesis. 1, 3

Updated 2025 ISTH Diagnostic Framework

• The revised ISTH criteria recognize that DIC progresses through phases: pre-DIC, early-phase DIC (compensated), and overt DIC. 4, 5
• Early-phase DIC is characterized by laboratory abnormalities (including normal or elevated fibrinogen) that precede clinical symptoms. 4
• The overt DIC scoring system includes platelet count, prothrombin time-INR, D-dimer levels (with revised thresholds at >3× and >7× upper normal limit), and fibrinogen, but fibrinogen is weighted less heavily because of its variability. 4

Clinical Pitfalls to Avoid

• Do not exclude DIC based on normal or elevated fibrinogen levels alone—this is a common error that delays diagnosis in early-phase disease. 1, 3
• Clotting parameters are usually normal unless DIC is fulminant, so screening must include fibrin markers (D-dimer, FDP) even when routine coagulation tests appear reassuring. 2
• In sepsis-induced coagulopathy, screen using the sepsis-induced coagulopathy score to detect early-phase DIC before overt consumption develops. 1, 4
• High fibrinogen in a patient with suspected DIC should raise concern for inadequate fibrinolysis and increased risk of thrombotic complications and organ dysfunction. 3

Disease-Specific Considerations

Sepsis-Associated DIC

• Endothelial dysfunction and inflammation drive acute-phase responses that maintain or elevate fibrinogen despite consumption. 1
• Plasminogen activator inhibitor-1 (PAI-1) levels are significantly higher in patients with high fibrinogen, further impairing fibrinolysis. 3

Malignancy-Associated DIC

• Acute promyelocytic leukemia presents with hyperfibrinolytic DIC where fibrinogen may be more rapidly depleted. 6
• In other hematologic malignancies, high fibrinogen correlates with increased organ failure and mortality. 3

Liver Disease Overlap

• Cirrhotic patients can have overlapping features of DIC with variable fibrinogen levels due to impaired hepatic synthesis, making interpretation particularly challenging. 7